Skip to main content
SpringerLink
Log in

Caring for Pregnant and Parenting Women with Opioid Use Disorder

  • Chapter
  • First Online:
Book cover Treating Opioid Use Disorder in General Medical Settings

  • 570 Accesses

Abstract

In parallel with the opioid overdose crisis in the US, rates of opioid use disorder (OUD) have increased during pregnancy. Untreated OUD is associated with poor maternal, perinatal, and neonatal outcomes, whereas people who receive evidence-based care with either methadone or buprenorphine have birth outcomes that are similar to people without OUD. Nonetheless, treatment, especially medication for opioid use disorder (MOUD), remains unavailable and underutilized during pregnancy. Postpartum, the year following delivery, is a critical and overlooked period as mood changes, medication discontinuation, and lapses in insurance coverage are common. People with OUD are overrepresented in maternal deaths, especially during the postpartum period, where opioid overdose is among the leading causes of mortality. Public health and public policy responses to OUD in pregnancy are increasingly misaligned as the growth of punitive policies defies evidence-based practice recommendations and harms pregnant and parenting people and their families.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Medicine ASoA. Public Policy Statement on Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids. 2017. https://www.asam.org/docs/default-source/public-policy-statements/substance-use-misuse-and-use-disorders-during-and-following-pregnancy.pdf?sfvrsn=644978c2_4. Accessed 20 March 2020.

  2. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009-2012. J Perinatol. 2015;35(8):650–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Substance Abuse and Mental Health Services Administration (SAMHSA). Results From the 2015 National Survey on Drug Use and Health: Detailed Tables. 2016.; https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.pdf.

  4. Kern-Goldberger AR, Huang Y, Polin M, et al. Opioid use disorder during antepartum and postpartum hospitalizations. Am J Perinatol. 2019. [ePub ahead of print].

    Google Scholar 

  5. Wen T, Batista N, Wright JD, et al. Postpartum readmissions among women with opioid use disorder. Am J Obstet Gynecol MFM. 2019;1(1):89–98.

    Article  PubMed  Google Scholar 

  6. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842–50.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934–40.

    Article  CAS  PubMed  Google Scholar 

  8. Ecker JL, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol. 2019;221(1):B5–28.

    Article  PubMed  Google Scholar 

  9. Reddy UM, Davis JM, Ren Z, et al. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol. 2017;130(1):10–28.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Schiff DM, Nielsen T, Terplan M, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. 2018;132(2):466–74.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Goldman-Mellor S, Margerison CE. Maternal drug-related death and suicide are leading causes of postpartum death in California. Am J Obstet Gynecol. 2019;221(5):489.e481-489.e489.

    Google Scholar 

  12. Smid MC, Stone NM, Baksh L, et al. Pregnancy-associated death in Utah: contribution of drug-induced deaths. Obstet Gynecol. 2019;133(6):1131–40.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Koch AR, Geller SE. Addressing maternal deaths due to violence: the Illinois experience. Am J Obstet Gynecol. 2017;217(5):556.e551–556.e556.

    Google Scholar 

  14. Illinois Perinatal Quality Collaborative (ILPQC). Mothers and Newborns affected by Opioids (MNO)-OB Initiative. 2019; http://ilpqc.org/?q=MNO-OB.

  15. Metz TD, Rovner P, Hoffman MC, Allshouse AA, Beckwith KM, Binswanger IA. Maternal deaths from suicide and overdose in Colorado, 2004–2012. Obstet Gynecol. 2016;128(6):1233–40.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81–94.

    Article  Google Scholar 

  17. Ondersma SJ, Chang G, Blake-Lamb T, et al. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. 2019;114(9):1683–93.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Klaman SL, Isaacs K, Leopold A, et al. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med. 2017;11(3):178.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mascola MA, Borders AE, Terplan M, Practice CO, Med ASA. Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):E81–94.

    Article  Google Scholar 

  21. Zuspan FP, Gumpel JA, Mejia-Zelaya A, Madden J, Davis R. Fetal stress from methadone withdrawal. Am J Obstet Gynecol. 1975;122(1):43–6.

    Article  CAS  PubMed  Google Scholar 

  22. McCarthy JJ, Leamon MH, Finnegan LP, Fassbender C. Opioid dependence and pregnancy: minimizing stress on the fetal brain. Am J Obstet Gynecol. 2017;216(3):226–31.

    Article  PubMed  Google Scholar 

  23. Terplan M, Laird HJ, Hand DJ, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;131(5):803–14.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dole VP, Nyswander M. The treatment of heroin addiction. JAMA. 1966;195(11):972.

    Article  Google Scholar 

  25. Kelty E, Hulse G. A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates. Drugs. 2017;77(11):1211–9.

    Article  CAS  PubMed  Google Scholar 

  26. Wachman EM, Saia K, Miller M, et al. Naltrexone treatment for pregnant women with opioid use disorder compared with matched buprenorphine control subjects. Clin Ther. 2019;41(9):1681–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Harper RG, Solish GI, Purow HM, Sang E, Panepinto WC. The effect of a methadone treatment program upon pregnant heroin addicts and their newborn infants. Pediatrics. 1974;54(3):300–5.

    Article  CAS  PubMed  Google Scholar 

  28. Baxter LE Sr, Campbell A, Deshields M, et al. Safe methadone induction and stabilization: report of an expert panel. J Addict Med. 2013;7(6):377–86.

    Article  CAS  PubMed  Google Scholar 

  29. McCarthy JJ, Jones HE, Terplan M, Rudolf VP, von Klimo MC. Changing outdated methadone regulations that harm pregnant patients. J Addict Med. 2020;15:93.

    Article  Google Scholar 

  30. McCarthy JJ, Vasti EJ, Leamon MH, Graas J, Ward C, Fassbender C. The use of serum methadone/metabolite ratios to monitor changing perinatal pharmacokinetics. J Addict Med. 2018;12(3):241–6.

    Article  CAS  PubMed  Google Scholar 

  31. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis. 2010;29(1):1–14.

    Article  PubMed  Google Scholar 

  32. Dashe JS, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol. 2002;100(6):1244–9.

    CAS  PubMed  Google Scholar 

  33. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol. 2003;189(2):312–7.

    Article  CAS  PubMed  Google Scholar 

  34. Cleary BJ, Eogan M, O'Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107(8):1482–92.

    Article  PubMed  Google Scholar 

  35. Jones HE, Jansson LM, O'Grady KE, Kaltenbach K. The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicol Teratol. 2013;39:110–5.

    Article  CAS  PubMed  Google Scholar 

  36. Pizarro D, Habli M, Grier M, Bombrys A, Sibai B, Livingston J. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abus Treat. 2011;40(3):295–8.

    Article  Google Scholar 

  37. Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction. 2010;105(12):2071–84.

    Article  PubMed  Google Scholar 

  38. Metz V, Jagsch R, Ebner N, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol Clin Exp. 2011;26(6):412–21.

    Google Scholar 

  39. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96(1–2):69–78.

    Article  CAS  PubMed  Google Scholar 

  40. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275–81.

    Article  PubMed  Google Scholar 

  41. Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67(10):1053–9.

    Article  CAS  PubMed  Google Scholar 

  42. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180(7):673–86.

    Article  PubMed  Google Scholar 

  44. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 2013;22(3):252–4.

    Article  PubMed  Google Scholar 

  45. Lund IO, Fischer G, Welle-Strand GK, et al. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse: Res Treat. 2013;7:61–74.

    CAS  Google Scholar 

  46. Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015;125(2):363–8.

    Article  CAS  PubMed  Google Scholar 

  47. Shiu JR, Ensom MH. Dosing and monitoring of methadone in pregnancy: literature review. Can J Hosp Pharm. 2012;65(5):380–6.

    PubMed  PubMed Central  Google Scholar 

  48. Bastian JR, Chen H, Zhang H, Rothenberger S, Tarter R, English D, Venkataramanan R, Caritis SN. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. Am J Obstet Gynecol. 2017;216(1):64.e1–64.e7.

    Google Scholar 

  49. Caritis SN, Bastian JR, Zhang H, et al. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol. 2017;217(4):459 e451–459 e456.

    Google Scholar 

  50. Krans EE, Campopiano M, Cleveland LM, Goodman DJ, Kilday D, Kendig S, Leffert LR, Main EK, Mitchell KT, O’Gurek DT, D’Oria R, McDaniel D, Terplan M. National partnership for maternal safety: consensus bundle on obstetric care for women with opioid use disorder. Obstet Gynecol. 2019;134(2):365–75.

    Article  PubMed  Google Scholar 

  51. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(6):747–57.

    Article  CAS  PubMed  Google Scholar 

  52. Terplan M, Garrett J, Hartmann K. Gestational age at enrollment and continued substance use among pregnant women in drug treatment. J Addict Dis. 2009;28(2):103–12.

    Article  PubMed  Google Scholar 

  53. Krans EE, Kim JY, James AE, Kelley D, Jarlenski MP. Medication-assisted treatment utilization among pregnant women with opioid use disorder. Obstet Gynecol. 2019;133(5):943–51.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Bachhuber MA, Mehta PK, Faherty LJ, Saloner B. Medicaid coverage of methadone maintenance and the use of opioid agonist therapy among pregnant women in specialty treatment. Med Care. 2017;55(12):985–90.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and disparities in receipt of pharmacotherapy among pregnant women in publicly funded treatment programs for opioid use disorder in the United States. J Subst Abus Treat. 2018;89:67–74.

    Article  Google Scholar 

  56. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–7.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? JAMA Intern Med. 2013;173(17):1571–2.

    Article  PubMed  Google Scholar 

  58. Bawor M, Dennis BB, Varenbut M, et al. Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015;6:21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Levine AR, Lundahl LH, Ledgerwood DM, Lisieski M, Rhodes GL, Greenwald MK. Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment. J Subst Abus Treat. 2015;54:37–43.

    Article  Google Scholar 

  60. Pallatino C, Chang JC, Krans EE. The intersection of intimate partner violence and substance use among women with opioid use disorder. Subst Abus. 2019;42:1–8.

    Google Scholar 

  61. Patrick SW, Buntin MB, Martin PR, et al. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states. Subst Abus. 2019;40(3):356–62.

    Article  PubMed  Google Scholar 

  62. Keyes KM, Cerda M, Brady JE, Havens JR, Galea S. Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States. Am J Public Health. 2014;104(2):e52–9.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Jackson A, Shannon L. Barriers to receiving substance abuse treatment among rural pregnant women in Kentucky. Matern Child Health J. 2012;16(9):1762–70.

    Article  PubMed  Google Scholar 

  64. Lander LR, Marshalek P, Yitayew M, Ford D, Sullivan CR, Gurka KK. Rural healthcare disparities: challenges and solutions for the pregnant opioid-dependent population. W V Med J. 2013;109(4):22–7.

    PubMed  Google Scholar 

  65. Kremer ME, Arora KS. Clinical, ethical, and legal considerations in pregnant women with opioid abuse. Obstet Gynecol. 2015;126(3):474–8.

    Article  CAS  PubMed  Google Scholar 

  66. Faherty LJ, Stein BD, Terplan M. Consensus guidelines and state policies: the gap between principle and practice at the intersection of substance use and pregnancy. Am J Obstetr Gynecol MFM. 2020;2:100137.

    Article  Google Scholar 

  67. Faherty LJ, Kranz AM, Russell-Fritch J, Patrick SW, Cantor J, Stein BD. Association of punitive and reporting state policies related to substance use in pregnancy with rates of neonatal abstinence syndrome. JAMA Netw Open. 2019;2(11):–e1914078.

    Google Scholar 

  68. Frazer Z, McConnell K, Jansson LM. Treatment for substance use disorders in pregnant women: motivators and barriers. Drug Alcohol Depend. 2019;205:107652.

    Article  PubMed  Google Scholar 

  69. Jones HE, Deppen K, Hudak ML, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014;210(4):302–10.

    Article  PubMed  Google Scholar 

  70. Hollander M, Jarlenski MP, Kim JY, James AE, Kelley D, Krans EE. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder. Am J Obstet Gynecol. 2019;220:502.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (extension for community healthcare outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20–4.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Katzman JG, Galloway K, Olivas C, et al. Expanding health care access through education: dissemination and implementation of the ECHO model. Mil Med. 2016;181(3):227–35.

    Article  PubMed  Google Scholar 

  73. Hager B, Hasselberg M, Arzubi E, et al. Leveraging behavioral health expertise: practices and potential of the project ECHO approach to virtually integrating care in underserved areas. Psychiatr Serv. 2018;69(4):366–9.

    Article  PubMed  Google Scholar 

  74. Krans EE, Zickmund SL, Rustgi VK, Park SY, Dunn SL, Schwarz EB. Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: a retrospective cohort study. Subst Abus. 2016;37(1):88–95.

    Article  PubMed  Google Scholar 

  75. Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35(5):358–63.

    Article  PubMed  PubMed Central  Google Scholar 

  76. ACOG Committee Opinion No. 757: screening for perinatal depression. Obstet Gynecol. 2018;132(5):e208–12.

    Article  Google Scholar 

  77. McLafferty LP, Becker M, Dresner N, et al. Guidelines for the management of pregnant women with substance use disorders. Psychosomatics. 2016;57(2):115–30.

    Article  PubMed  Google Scholar 

  78. Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174(8):738–47.

    Article  PubMed  Google Scholar 

  79. O'Rourke-Suchoff D, Sobel L, Holland E, Perkins R, Saia K, Bell S. The labor and birth experience of women with opioid use disorder: a qualitative study. Women Birth : Journal of the Australian College of Midwives. 2020;33:592.

    Article  Google Scholar 

  80. Ko JY, Tong VT, Haight SC, et al. Obstetrician-gynecologists' practices and attitudes on substance use screening during pregnancy. J Perinatol. 2020;40(3):422–32.

    Article  PubMed  Google Scholar 

  81. Leknes S, Tracey I. A common neurobiology for pain and pleasure. Nat Rev Neurosci. 2008;9(4):314–20.

    Article  CAS  PubMed  Google Scholar 

  82. Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abus Treat. 2017;77:26–30.

    Article  Google Scholar 

  83. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760–73.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Sullivan M. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524–32.

    Article  Google Scholar 

  85. Shih YW, Tsai HY, Lin FS, et al. Effects of positive and negative expectations on human pain perception engage separate but interrelated and dependently regulated cerebral mechanisms. J Neurosci. 2019;39(7):1261–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Martin CE, Johnson E, Wechter ME, Leserman J, Zolnoun DA. Catastrophizing: a predictor of persistent pain among women with endometriosis at 1 year. Hum Reprod. 2011;26(11):3078–84.

    Article  Google Scholar 

  87. Martel MO, Jamison RN, Wasan AD, Edwards RR. The association between catastrophizing and craving in patients with chronic pain prescribed opioid therapy: a preliminary analysis. Pain Med (Malden, Mass). 2014;15(10):1757–64.

    Article  Google Scholar 

  88. Finan PH, Carroll CP, Moscou-Jackson G, et al. Daily opioid use fluctuates as a function of pain, catastrophizing, and affect in patients with sickle cell disease: an electronic daily diary analysis. J Pain. 2018;19(1):46–56.

    Article  PubMed  Google Scholar 

  89. Sharifzadeh Y, Kao MC, Sturgeon JA, Rico TJ, Mackey S, Darnall BD. Pain catastrophizing moderates relationships between pain intensity and opioid prescription: nonlinear sex differences revealed using a learning health system. Anesthesiology. 2017;127(1):136–46.

    Article  PubMed  Google Scholar 

  90. McCracken LM, Dhingra L. A short version of the Pain Anxiety Symptoms Scale (PASS-20): preliminary development and validity. Pain Res Manag. 2002;7(1):45–50.

    Article  PubMed  Google Scholar 

  91. Darnall BD, Sturgeon JA, Kao MC, Hah JM, Mackey SC. From catastrophizing to recovery: a pilot study of a single-session treatment for pain catastrophizing. J Pain Res. 2014;7:219–26.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Nicholls JL, Azam MA, Burns LC, et al. Psychological treatments for the management of postsurgical pain: a systematic review of randomized controlled trials. Patient Relat Outcome Meas. 2018;9:49–64.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Barry DT, Beitel M, Cutter CJ, et al. An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain. Drug Alcohol Depend. 2019;194:460–7.

    Article  PubMed  Google Scholar 

  94. SAMHSA. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18–5054. Rockville: Substance Abuse and Mental Health Services Administration; 2018.

    Google Scholar 

  95. Vilkins AL, Bagley SM, Hahn KA, et al. Comparison of post-cesarean section opioid analgesic requirements in women with opioid use disorder treated with methadone or buprenorphine. J Addict Med. 2017;11(5):397–401.

    Article  CAS  PubMed  Google Scholar 

  96. Zgierska AE, Miller MM, Rabago DP, et al. Language matters: it is time we change how we talk about addiction and its treatment. J Addict Med. 2020;15:10.

    Article  Google Scholar 

  97. Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11(3):163–73.

    Article  PubMed  Google Scholar 

  98. Tully KP, Stuebe AM, Verbiest SB. The fourth trimester: a critical transition period with unmet maternal health needs. Am J Obstet Gynecol. 2017;217(1):37–41.

    Article  PubMed  Google Scholar 

  99. Barthel D, Kriston L, Barkmann C, et al. Longitudinal course of ante- and postpartum generalized anxiety symptoms and associated factors in West-African women from Ghana and Cote d'Ivoire. J Affect Disord. 2016;197:125–33.

    Article  PubMed  Google Scholar 

  100. Daw JR, Hatfield LA, Swartz K, Sommers BD. Women in the United States experience high rates of coverage 'Churn' in months before and after childbirth. Health Affairs (Project Hope). 2017;36(4):598–606.

    Article  Google Scholar 

  101. Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. 2015;149:225–31.

    Article  PubMed  Google Scholar 

  102. Wilder CM, Hosta D, Winhusen T. Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. J Subst Abus Treat. 2017;80:33–6.

    Article  Google Scholar 

  103. Gemmill A, Kiang MV, Alexander MJ. Trends in pregnancy-associated mortality involving opioids in the United States, 2007-2016. Am J Obstet Gynecol. 2019;220(1):115–6.

    Article  PubMed  Google Scholar 

  104. Nielsen T, Bernson D, Terplan M, et al. Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery. Addiction. 2019;115:291.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abus Treat. 2007;32(1):19–25.

    Article  Google Scholar 

  106. O'Connor AB, Uhler B, O'Brien LM, Knuppel K. Predictors of treatment retention in postpartum women prescribed buprenorphine during pregnancy. J Subst Abus Treat. 2018;86:26–9.

    Article  Google Scholar 

  107. Smith-Nielsen J, Matthey S, Lange T, Vaever MS. Validation of the Edinburgh Postnatal Depression Scale against both DSM-5 and ICD-10 diagnostic criteria for depression. BMC Psychiatry. 2018;18(1):393.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Bogen DL, Perel JM, Helsel JC, et al. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. Psychopharmacology. 2013;225(2):441–51.

    Article  CAS  PubMed  Google Scholar 

  109. Pace CA, Kaminetzky LB, Winter M, et al. Postpartum changes in methadone maintenance dose. J Subst Abus Treat. 2014;47(3):229–32.

    Article  Google Scholar 

  110. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014(2):Cd002207.

    Google Scholar 

  111. Wright TE. Integrating reproductive health services into opioid treatment facilities: a missed opportunity to prevent opioid-exposed pregnancies and improve the health of women who use drugs. J Addict Med. 2019;13(6):420–1.

    Article  PubMed  Google Scholar 

  112. Krans EE, Kim JY, James AE 3rd, Kelley DK, Jarlenski M. Postpartum contraceptive use and interpregnancy interval among women with opioid use disorder. Drug Alcohol Depend. 2018;185:207–13.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Kotha A, Chen BA, Lewis L, Dunn S, Himes KP, Krans EE. Prenatal intent and postpartum receipt of long-acting reversible contraception among women receiving medication-assisted treatment for opioid use disorder. Contraception. 2019;99(1):36–41.

    Article  PubMed  Google Scholar 

  114. ACOG. Committee Opinion No. 670: immediate postpartum long-acting reversible contraception. Obstet Gynecol. 2016;128(2):e32–7.

    Article  Google Scholar 

  115. Hughes PH. Behind the wall of respect: community experiments in heroin addiction control. Chicago: University of Chicago Press; 1977.

    Google Scholar 

  116. Bourgois P. In search of respect: selling crack in El Barrio. 2nd ed. New York: Cambridge University Press; 2003.

    Google Scholar 

  117. Bourgois P, Schonberg J. Righteous Dopefiend. Berkeley: University of California Press; 2009.

    Google Scholar 

  118. Spillane J. The making of an underground market: drug selling in Chicago, 1900-1940. J Soc Hist. 1998;32(1):27–47.

    Article  Google Scholar 

  119. Hughes PH, Barker NW, Crawford GA, Jaffe JH. The natural history of a heroin epidemic. Am J Public Health. 1972;62(7):995–1001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Patrick SW, Faherty LJ, Dick AW, Scott TA, Dudley J, Stein BD. Association among county-level economic factors, clinician supply, metropolitan or rural location, and neonatal abstinence syndrome. JAMA. 2019;321(4):385–93.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Netherland J, Hansen H. White opioids: pharmaceutical race and the war on drugs that wasn't. BioSocieties. 2017;12(2):217–38.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Roberts SCM, Mericle AA, Subbaraman MS, et al. State policies targeting alcohol use during pregnancy and alcohol use among pregnant women 1985-2016: evidence from the behavioral risk factor surveillance system. Womens Health Issues. 2019;29(3):213–21.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Thomas S, Treffers R, Berglas NF, Drabble L, Roberts SCM. Drug use during pregnancy policies in the United States from 1970 to 2016. Contemp Drug Probl. 2018;45(4):441–59.

    Article  Google Scholar 

  124. Kozhimannil KB, Dowd WN, Ali MM, Novak P, Chen J. Substance use disorder treatment admissions and state-level prenatal substance use policies: evidence from a national treatment database. Addict Behav. 2019;90:272–7.

    Article  PubMed  Google Scholar 

  125. Chasnoff IJ, Landress HJ, Barrett ME. The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med. 1990;322(17):1202–6.

    Article  CAS  PubMed  Google Scholar 

  126. Roberts SC, Nuru-Jeter A. Universal screening for alcohol and drug use and racial disparities in child protective services reporting. J Behav Health Serv Res. 2012;39(1):3–16.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Wildeman C, Emanuel N. Cumulative risks of foster care placement by age 18 for US children, 2000–2011. PLoS One. 2014;9(3):e92785.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  128. Meinhofer A, Anglero-Diaz Y. Trends in Foster Care entry among children removed from their homes because of parental drug use, 2000 to 2017. JAMA Pediatr. 2019; [ePub ahead of print].

    Google Scholar 

  129. Knight KR. Addicted. pregnant. poor. Durham: Duke University Press; 2015.

    Book  Google Scholar 

  130. Falletta L, Hamilton K, Fischbein R, Aultman J, Kinney B, Kenne D. Perceptions of child protective services among pregnant or recently pregnant, opioid-using women in substance abuse treatment. Child Abuse Negl. 2018;79:125–35.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friends Research Institute, Baltimore, MD, USA

    Mishka Terplan

  2. Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA, USA

    Caitlin E. Martin

  3. Obstetrics and Gynecology, Northwestern University, Chicago, IL, USA

    Ashish Premkumar

  4. Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA, USA

    Elizabeth E. Krans

Authors
  1. Mishka Terplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caitlin E. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ashish Premkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth E. Krans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mishka Terplan .

Editor information

Editors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Charlestown, MA, USA

    Sarah E. Wakeman

  2. Brown University, The Miriam and Rhode Island Hospitals, Providence, RI, USA

    Josiah D. Rich

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Terplan, M., Martin, C.E., Premkumar, A., Krans, E.E. (2021). Caring for Pregnant and Parenting Women with Opioid Use Disorder. In: Wakeman, S.E., Rich, J.D. (eds) Treating Opioid Use Disorder in General Medical Settings. Springer, Cham. https://doi.org/10.1007/978-3-030-80818-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80818-1_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80817-4

  • Online ISBN: 978-3-030-80818-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation